1237

Informations de base

• Disponible sur:
• English
• Français

Introducing the EarlyTect Colon Cancer Test, a groundbreaking solution in the field of colorectal cancer diagnosis. Developed and approved by the prestigious Korea Ministry of Food and Drug Safety, this test has undergone rigorous clinical trials at leading medical centers like Yonsei Medical Center, Severance Hospital, and Severance Check-up Center.

With a focus on precision and accuracy, the EarlyTect Colon Cancer Test utilizes fecal DNA analysis to provide a qualitative real-time PCR diagnosis of colorectal cancer. By measuring the presence of methylated Syndecan-2, a clinically significant biomarker associated with precancerous lesions of CRC, this test achieves an impressive 90% sensitivity and specificity.

It's important to note that the EarlyTect Colon Cancer Test is not intended to confirm the presence of colorectal cancer but serves as a highly reliable screening tool. Therefore, if a subject tests positive, it indicates the potential existence of CRC or precancerous lesions of CRC, warranting further medical evaluation.

Product Standard:

- Cancer Type: Colorectal Cancer
- Subject: Asymptomatic individuals seeking colorectal cancer screening
- Biomarker: SDC2 mRNA

To cater to the unique needs of our customers, pricing and transaction conditions are negotiable. Kindly request a quote, and our team will provide you with the necessary information to proceed with the transaction.